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1.ABSTRACT 
 
Pseudohypoparathyroidism is a term used to identify a heterogeneous group of rare diseases 
associated with genetic and/or epigenetic defects at the imprinted GNAS locus, that encodes also 
for the α subunit of the stimulatory G protein (Gsα). 
Most GNAS-based disorders share the common feature of episodic de novo formation of 
heterotopic ossifications (HO), a pathological formation of bone in extra-skeletal tissues. The 
mosaic tissue distribution of HOs suggested that their pathogenesis involved the abnormal 
differentiation of precursor cells located in subcutaneous tissues, mesenchymal stem cells, and 
that GNAS defects provided a sensitized background promoting osteoblastogenesis.  
This study attempted to clarify the molecular mechanisms underlying HO formation in GNAS-
related diseases, as, although the growing knowledge, they are not completely understood. To this 
aim, we developed an in vitro human model of adipose-derived mesenchymal stem cells (ADMSCs) 
from surgically removed samples of subcutaneous fat of healthy donors.  
Firstly, we confirmed the ability of our ADMSCs to differentiate into osteoblasts and adipocytes by 
specific biochemical assays, stainings and lineage-specific markers expression. We determined that 
in vitro manipulation did not affect the maintenance of GNAS imprinting status. Finally, In order to 
investigate the effect of GNAS haploinsufficiency, we transfected ADMSCs with siRNAs designed to 
specifically silence different GNAS transcripts, obtaining an efficiency of about 75% at day 4, which 
decreased at about 50% at day 21. Then, we analyzed the expression of different osteogenic 
markers in GNAS-silenced ADMSCs and we observed that Gs alpha haploinsufficiency promoted 
their commitment towards the osteoblastic differentiation.  
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In conclusion, our study showed that ADMSCs are a good model to study the osteogenic 
differentiation and the formation of HOs in GNAS-related diseases. In particular, we observed that 
GNAS silencing promotes ADMSCs commitment towards the osteoblast lineage, even in the 
absence of additional osteogenic-inducing stimuli. Moreover, no significant differences due to use 
of different GNAS siRNAs were observed, further supporting the hypothesis that the formation of 
ectopic bone in GNAS-related diseases is predominantly Gsα-mediated.  
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2. INTRODUCTION 
2.1. Albright hereditary osteodystrophy, Pseudohypoparathyroidism and GNAS-
related diseases 
Pseudohypoparathyroidism (PHP) is the firstly described syndrome of hormone resistance and it 
was reported by Fuller Albright in 1942 (Albright F. et al, 1942). Albright reported patients with 
normal renal function, in whom hypocalcemia and hyperphosphatemia were associated with a 
reduced calcemic and phosphaturic response to injected bovine parathyroid extract compared 
with patients with primary hypoparathyroidism, leading to the hypothesis of a resistance to 
parathyroid hormone (PTH) action. Subsequent studies, describing parathyroid hyperplasia and 
elevation of immunoreactive serum PTH in untreated PHP patients, confirmed that PTH resistance 
was indeed the underlying defect (Mann J.B. et al 1962; Tashjian A.H. et al, 1966).  
PHP is classically differentiated into different subtypes according to the presence or absence of 
Albright's hereditary osteodystrophy (AHO) features and to the underlying molecular defect at the 
GNAS locus. 
2.1.1 Clinical phenotype of PHP subtypes  
AHO is a term used to describe a collection of signs and symptoms, including short stature, 
moderate to severe obesity, mental retardation and/or behavioural defects, round face with a 
short nose and short neck, brachydactyly (mainly of fourth and fifth fingers) and the formation of 
ectopic bone (Farfel Z. et al., 1986). In particular, heterotopic ossifications are a distinctive signs of 
AHO (Eyre WG. Et al., 1971), and being the investigation of the molecular mechanism underlining 
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their formation the main aim of this thesis, they which will be deeply discussed in the next 
paragraphs.  
Main PHP subtypes, PHP type 1A (PHP-1A) and type 1B (PHP-1B), differ for the presence of genetic 
and/or epigenetic defects affecting the GNAS locus, and for the presence/absence of AHO 
features.  
PHP-1A is a clinical condition characterized by hormone resistance (PTH and TSH, but frequently 
also to gonadotropins and GHRH) and by AHO manifestations (Levine MA et al., 1983). Several 
studies showed that approximately 70% of PHP-1A patients presented inactivating mutations on 
the maternal allele of GNAS exons 1-13 (Elli FM. et al., 2013; Thiele et al., 2015; Lemos MC. et al., 
2015; Weinstein LS et al., 1990; Mantovani et al., 2007; Ham H-J et al., 2015; Lin MH et al., 2015).  
The same mutations, when affecting the paternal allele, may lead to 
Pseudopseudohypoparathyroidism (PPHP) or to progressive osseous heteroplasia (POH) (Adegbite 
NS et al., 2008; Shore EM et al., 2002). PPHP patients exhibit AHO features without evidence for 
hormone resistance, instead POH patients are characterized by subcutaneous ossifications that 
progress into deep connective tissues (Shore et al., 2002; Cairns et al., 2013). 
PHP-1B patients classically show a resistance to PTH, and frequently to TSH, without any signs of 
AHO. PHP-1B is caused by sporadic or genetic based GNAS methylation defects (Schipani, E., et al. 
1995; Jobert, A.S., et al. 1998; Turan et al., 2013). 
In the 1960’s, it was proposed the existence of other PHP subtypes, such as PHP-1C, that is 
characterized by the presence of hormone resistance and AHO, but normal activity of the 
stimulatory G protein (Brix B. et al., 2014; Thiele S et al., 2011; Mantovani G., 2011).  
Another rare subtype of PHP is isolated osteoma cutis (OC), which is characterized by the 
formation of heterotopic ossifications in the absence of hormone resistance or AHO features. OC 
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differs from POH, for the non progressive nature of heterotopic ossifications, that are limited to 
dermis and subcutaneous tissues, although it can be confused with an initial form of POH. (Shore 
et al., 2010) (Tab.1). 
Finally, there is also a related disorder termed PHP type 2, which is characterized by hypocalcemia, 
PTH resistance, absence of AHO and no GNAS mutations. In these patients, it was observed a 
normal cAMP response to PTH associated with no phosphaturic response, which probably 
indicates that the causative defect is distal to cAMP generation, possibly due to molecular defects 
affecting other molecules involved in the PTH-mediated signal transduction pathway (such as 
mutations in PRKAR1A or PDE4D genes) (Linglart et al., 2011; Michot et al., 2012) or it derives from 
acquired causes such as vitamin D deficiency (Akin et al., 2010). 
 
Tab 1: Classifications of PHP and GNAS-related diseases. 
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2.1.2 Physiopathology of AHO, PHP and GNAS related diseases 
PHP pathophysiology was unraveled after the discovery of PTH receptor and its signal transduction 
pathway (Aurbach et al., 1992). PTH is a short half-life hormone secreted by the parathyroid 
glands and degraded by the liver. PTH maintains calcium and phosphate homeostasis acting 
mainly on two target tissues, bone and kidney. PTH secretion is regulated by calcium plasma 
concentration with a negative feedback mechanism. At kidney level, PTH enhances the absorption 
of calcium, reduces the tubular reabsorption of phosphorus and stimulates the activation of renal 
1-α-hydroxylase, the enzyme that produces the active form of vitamin D. PTH also acts in the 
intestine, where it promotes intestinal calcium absorption (Brown AU et al., 1983; Potts JT et al., 
1996; Diaz R et al., 1999). 
Administration of exogenous biologically PTH active forms in PHP patients fails to induce an 
appropriate increase in urinary levels of phosphate and cAMP, demonstrating the PTH resistance 
(Breslau NA et al., 1988; Drezner MK et al., 1976; Levine M et al., 2000; Chase LR et al., 1969). 
However, the phenomenon of hormone resistance seems to be restricted to kidney proximal 
tubules, since the PTH action is still present, although weakened, at the level of other target 
tissues such as bone (Ish-Shalom S et al., 1996; Murray T et al., 1993) and the ascending thick 
tubule (Stone M et al., 1993). This residual activity, associated with a high PTH concentration, may 
explain the preservation of normocalcemia for long periods of time in some PHP patients. (Rao DS 
et al., 1985; Rodriguez HJ et al., 1974; Akin L et al., 2010) 
At the molecular level, the binding of PTH to its receptor, the parathyoid hormone 1 receptor 
(PTH1R), leads to the activation of the α subunit of the stimulatory G protein, which in turns 
stimulate the adenyl cyclase determining an increase of cAMP synthesis. cAMP is a second 
messenger able to regulate the activity of different downstream targets, including the protein 
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kinase A (PKA), which consists of two regulatory and two catalytic subunits. When the intracellular 
concentration of cAMP increases, cAMP molecules bind to PKA regulatory subunits, inducing a 
conformational change that causes its separation from the catalytic subunit. In this way PKA 
catalytic subunits activate and phosphorylate downstream effectors, including the cAMP response 
element-binding protein (CREB) that, at the nuclear level, induces the transcription of cAMP 
responsive genes (Peri A et al., 2001; Plagge A et al., 2008, Lania A. et al. 2001)(Fig.2). 
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Fig 2. Schematic diagram of the cAMP pathway. Upon activation of a G-protein coupled receptor, the 
trimeric Gαβγ protein dissociates into the active Gα subunit, loaded with GTP. The GTP-loaded Gα activates 
the adenylyl cyclase (AC), which generates cAMP from ATP. Next, cAMP binds to the regulatory subunits (R) 
of the PKA and induces dissociation of the holoenzyme. The catalytic subunits (C) can then phosphorylate 
cAMP response element-binding protein (CREB) leading to the activation of cAMP-inducible genes. Such 
regulation of gene expression by cAMP plays important roles in controlling the proliferation, survival, and 
differentiation of cells. 
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2.2. The complex imprinted GNAS locus 
The GNAS locus is a single copy gene that map in 20q13.2-13.3 position (Fig.3), spanning over 20 
kilobases, which presents a high degree of conservation of structure and regulation with its 
murine homolog Gnas, mapping on the distal portion of the chromosome 2 (Weinstein LS et al., 
2001). 
 
Fig 3: The GNAS locus is located on the distal long arm of chromosome 20. 
GNAS is a complex locus because, using different promoters and first exons, it generates multiple 
transcripts (G-protein α subunit (Gsα); Neuroendocrine-specific protein 55 (NESP55); Extra large 
αs (XLαs); antisense transcript (AS) and A/B) and it is subject to imprinting (Bastepe M et al., 2007; 
Weinstein LS et al., 2001). 
 
Fig 4.: Organization and imprinting of the GNAS complex locus 
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GNAS locus contains four distinct differential methylated regions (DMRs): three methylated on the 
maternal allele, comprising the promoter of AS, XLαs and A/B transcripts, and one methylated on 
the paternal allele, which contains the promoter of the NESP55-specific exon 1 (Fig.4).  
NESP55 is encoded by its specific exon 1, which splices onto the common downstream 2-13 GNAS 
exons, that codify for its 3 'untranslated region (3' UTR) (Weinstein LS et al., 2004). 
A second alternative promoter, located 11 kb downstream of NESP55-specific exon 1 and 35 kb 
upstream of Gsα-specific exon 1, produces the transcript known as XLαs. Various studies 
demonstrated that XLαs is able to act in a manner similar to Gsα in vitro, in accordance with the 
high degree of similarity between XLαs and Gsα (Klemke et al., 2000; Linglart et al., 2006; Bastepe 
et al., 2002).  
About 2.5 kb upstream of the Gsα promoter lies the promoter that drives the expression of the 
transcript termed A/B (1A in mouse) (Ishikawa et al., 1990; Swaroop et al., 1991). The first exon of 
the A/B transcript, as NESP55 and XLαs first exons, splices onto GNAS exons 2-13. The A/B 
transcript does not contain an in-frame translation initiation codon, thus it is uncertain whether it 
is translated into a protein (Ishikawa et al., 1990).  
The main genetic product of GNAS is Gsα, originated from the most downstream promoter, which 
is subject to tissue-specific imprinting, or rather it shows a biallelic expression except in selected 
tissues, where its expression is almost exclusively maternal (Mantovani G et al., 2002). 
2.2.1 Genetic and Epigenetic defects causing AHO, PHP and GNAS-related diseases 
The different forms of PHP are due to molecular defects affecting the GNAS gene, that lead to a 
decreased expression and/or activity of the alpha-subunit of the stimulatory G protein (Gsα).  
The first heterozygous Gsα inactivating mutation was described in 1990 by Pattern et colleagues 
(Pattern JL et al., 1990). Since then, several mutations located throughout the gene were 
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identified, with a detection rate of about 70% in PHP-1A patients (Elli et al., 2013). Most of these 
genetic defects are private mutations, and the few recurrent mutations probably derived from the 
presence of a common molecular mechanism, rather than by a founder effect (Elli et al., 2013).  
The presence of a mutation is associated with the development of the disease and a recurrence 
risk in the offspring of 50%, then performing the genetic analysis allows the diagnosis and the 
genetic counseling.  
In the recent years, several research groups looked for the existence of new molecular defects 
associated with PHP-1A in patients with no detectable GNAS point mutations. In particular, 
different works identified GNAS epigenetic defects (classically associated to PHP-1B) in a subgroup 
of patients with PHP and some features of AHO, suggesting a molecular overlap between PHP-1A 
and 1B (deNanclares et al ., 2007; Mariot et al., 2008; Mantovani G. et al., 2008; Elli et al., 2013). 
Recently, few cases of PHP patients with deletions of the long arm of chromosome 20, which 
totally or partially removed GNAS, have been reported. To date, only an inversion involving GNAS 
has been described (Fernandez-Rebollo et al., 2008).  
GNAS inactivating mutations that lead to PHP-1A and PPHP are mainly missense and nonsense 
point variations, but also splice site mutations and insertions/deletions can lead to the disorder. 
The expression analysis of samples from patients revealed the presence of haploinsufficiency, a 
reduction of approximately 50% of both Gsα protein and mRNA levels, thus confirming the 
inactivating nature of mutations (Farfel Z et al., 1980; Levine MA et al., 1983; Radeke HH et al., 
1986). 
PHP-1A and PPHP may be present within the same family and the phenotype of the progeny 
seems to depend upon the gender of the parent who transmitted the molecular defect. In 
particular, as predicted by the imprinted nature of Gsα, the paternal transmission of the mutation 
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probably determines the PPHP phenotype, while the maternal inheritance causes PHP-1A (Rickard 
SJ et al., 2003; Wilson LC et al., 1994; Germain-Lee et al., 2002; Mantovani et al., 2002). 
Paternally inherited mutations showed to be associated also with the POH phenotype (Shore et 
al., 2002). These observations lead to hypothesis that POH likely represents the most severe 
presentation among the spectrum of GNAS-related disorders (Bastepe et al., 2005). 
Activating and inactivating GNAS mutations lead to opposite effects on cAMP generation, which 
most likely explain the opposite effects on endocrine function and osteoblast development. In 
particular, it was shown that activating Gsα mutations and increased cAMP levels inhibited 
osteoblast differentiation, leading to fibrous dysplasia of bone (FD), while inactivating mutations 
appeared to promote osteoblast differentiation, leading to the formation of ectopic ossifications 
in AHO and in POH (Reitzik M et al., 1975; Happle R, 1986; Sarkar AK et al., 1993; Weinstein LS et 
al., 2001). These opposite effects on osteoblast differentiation suggested that the Gsα/cAMP 
pathway is involved in the regulation of osteoblastogenesis.  
Genomic imprinting is an epigenetic mechanism of gene regulation, essential for normal 
development in mammals, that determines the expression of only one allele according to its 
parental origin. Epigenetic marks, including DNA methylation and histone methylation, are 
established in primordial germ cells (sperm or egg cells) of parents, than maintained through 
mitotic cell divisions in the somatic cells of the progeny (Horsthemke B. 2010). The DNA 
methylation pattern of DMRs is maintained by regulatory sequences called imprinting control 
regions (ICRs). 
Similar to other biological process, also genetic imprinting is subject to a certain, albeit low, error 
rate and, actually, there is no evidence that aberrant imprinting can be repaired after fertilization. 
Three categories of imprinting defects have been described, according to the moment they arose 
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in the lifespan of an organism: defects in the erasure, the establishment or the maintenance of 
imprinting (Horsthemke B. 2010). 
Moreover, an imprinting defect may be further differentiated into a primary or a secondary 
epimutation. The term primary epimutation refers to an aberrant DNA methylation or histone 
modification pattern occurred in the absence of a DNA genetic mutation, while a secondary 
epimutation occurs as a direct consequence of a primary DNA genetic defect (Buiting et al., 2003; 
Horsthemke, 2006). In particular, a genetic mutation may affect an ICR at a given locus (cis-acting 
defect) or affect a regulatory factor encoded somewhere else in the genome (trans-acting DNA 
defect). Almost all DNA mutations known to cause an imprinting defect were in cis microdeletions 
of few hundred to thousand base pairs, while point mutations in ICRs seemed to be rare (Demars 
et al., 2010). Secondary epimutations, that are associated with a 50% recurrence risk, can occur de 
novo or can be transmitted from an affected patient or a carrier to the offspring.  
The imprinting defect of PHP-1B patients is represented by a paternal-specific pattern of 
methylation pattern at both parental alleles. The genetic-based form of PHP-1B, which represents 
about the 15-20% of cases, recurs with an autosomal dominant mode of inheritance (AD-PHP-1B). 
AD-PHP-1B patients show a loss of imprinting (LOI) limited to the GNAS A/B DMR, a loss of 
methylation (LOM), secondary to deletions on the maternal allele of the ICR within STX16 or 
NESP55 (Bastepe M et al., 2003; Linglart A et al., 2005; Bastepe M et al., 2005; Richard N et al., 
2012; Elli FM et al., 2014). Few familial maternally inherited deletions have been identified, 
leading to a LOI affecting all four GNAS DMRs (Chillambhi S et al., 2010; Rezwan FI et al., 2015; 
Takatani Ret al., 2016).  
Most PHP-1B patient are sporadic, which means no primary genetic defect has been detected, and 
probably are affected by primary epimutations. They present with a broad LOI affecting all four 
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GNAS DMRs. In about the 10% of PHP-1B patients, it was demonstrated the LOI was secondary to 
a complete or a segmental paternal uniparental disomy of the chromosome 20 (patUPD20) 
(Bastepe M et al., 2001; Fernández-Rebollo E et al., 2010; Dixit A et al., 2013; Takatani R et al., 
2015; Maupetit-Méhouas S et al., 2013). 
2.3. Heterotopic Ossification in AHO, PHP and GNAS-related diseases 
Disorders associated with GNAS inactivating defects share the common feature of de novo 
formation of heterotopic bone (HO) in skin and subcutaneous tissues. The HO is qualitatively 
normal bone developing through processes similar to the events typical of normal embryonic bone 
formation and of bone regeneration during fracture healing. Probably, it is a consequence of a 
dysregulation of the cell-fate determination of precursor cells present in subcutaneous tissues, 
due to an inappropriate induction of the bone formation program. As a matter of fact, bone 
formation requires the presence of precursor cells with the potential to differentiate into bone, a 
permissive microenvironment, and an inducing event.  
Hereditary forms of HO can be broadly divided into superficial HO, characterized by bone 
formation limited to superficial epidermal tissues, and progressive HO, in which ossifications 
gradually progress into deep connective tissues. Osteoma cutis, AHO/PPHP and PHP-1A/C are 
characterized by the formation of non-progressive HO, while in progressive osseous heteroplasia 
(POH) HOs are progressive (Kaplan et al., 1994). 
2.3.1 Clinical presentations of hereditary HO  
In non-progressive forms, HOs present later in life and are restricted to cutaneous and 
subcutaneous tissue, while, in progressive forms, HOs start developing during infancy in 
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subcutaneous tissues and progress during childhood into skeletal muscles and deep connective 
tissues (Fig.5). 
Patients with HO show a wide range of problems due to the mechanical effects of hard tissue 
formation in extraskeletal sites, which include pain, loss of joint mobility, skin ulceration, muscle 
and neurovascular entrapment, and prosthetic limb fitting difficulties (Wick L et al., 2005; Potter et 
al., 2010).  
 
Fig.5 Characteristic clinical features of non progressive form Of HO (1), and progressive POH (2) 
 
2.3.2 Ectopic ossifications pathophysiology 
Different authors postulated that HO formation needs the concomitant presence of precursor cells 
with the potential to differentiate into bone, inducing triggering events and a permissive micro-
environment, and that depends on the loss of the fine balance between pro-osteogenic and osteo-
inhibitory influences acting both locally and systemically (Balboni T. et al,2006; Yang Y et al., 2008; 
McCarty et al., 2005). 
The mosaic nature of HO in GNAS-related disorders suggested that GNAS defects provide a 
sensitized background for ectopic osteoblast differentiation (Zhang S et al., 2012; Bertaux K., 2005; 
Bertaux K., 2006; Teplyuk et al., 2008; Yeh GL et al., 2000; Day TF et al., 2008; Regard JB et al., 
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2013.). Over time, several different cell populations have been proposed as HO-forming precursor 
cells, and the preponderance of evidence suggested that mesenchymal, not endodermal or 
ectodermal, populations are major contributors (Lixin K. et al, 2013; Kan L. et al., 2014). 
Given the inverse relationship between adipogenesis and osteogenesis, a role for GNAS in the 
osteogenic differentiation of adipose-derived mesenchymal progenitor cells was suggested (Zhang 
S et al., 2012; Bertaux K., 2005; Bertaux K., 2006; Teplyuk et al., 2008; Yeh GL et al., 2000; Day TF 
et al., 2008; Regard JB et al., 2013 ; R.J. Pignolo. et al., 2011). 
2.3.3 In vitro and animal models to study HO 
The mouse with the Oed-Sml point missense mutation in exon 6 of Gnas locus was the first used 
animal model to study subcutaneous ossifications related to Gsα deficiency. Earlier results 
indicated that Gsα signaling pathway played a key role in preventing ectopic bone formation 
(Cheeseman et al., 2012). 
Using a mouse Gnas knockout model, Pignolo and collaborators demonstrated that the 
heterozygous inactivation of Gnas abrogated the upregulation of multiple transcripts that 
normally occurred with osteoblast differentiation of adipose stromal cells in vitro. In addition, 
their data supported the concept that GNAS is a key factor in the regulation of lineage the 
switching between osteoblast and adipocyte fates and that its role may be to prevent bone 
formation in tissues where bone should not form (Pignolo et al., 2011). As a matter of fact, 
transcriptional changes in Gnas +/- mice soft tissue stem cells were accompanied by accelerated 
osteoblast differentiation, enhanced expression of osteogenic markers and development of 
subcutaneous HO in vivo (Cheeseman MT et al, 2012; Zhang S et al., 2012). 
In order to extend studies of the role of Gs alpha function in vivo, a mouse model with locally 
restricted inactivation of Gs alpha was generated crossing hRen-Cre mice (transgenic mouse line 
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that expresses Cre-recombinase) with a mouse strain in which exon 1 of the Gnas gene was 
flanked by loxP sites. Mice phenotype consisted of marked skeletal malformations of the 
forelimbs, shortened and fused extremity of bones, and of extraskeletal ossifications in the 
subcutis and in skeletal muscles, associated with physiological plasma calcium, phosphate and PTH 
levels (Castrop H. et al., 2007). 
2.4. Mesenchymal stem cells 
Stem cells are distinguished from other cell types by two important characteristics: the self-
renewal, ability to go through numerous cycles of cell division maintaining the undifferentiated 
state, and potency, capacity to differentiate into specialized cell types (Davis et al., 2008). Stem 
cells can be embryonic or adult-derived (Hyun et al., 2010). Embryonic stem cells can further 
divided into totipotent, with the ability to differentiate into every type of cell in the body, and 
pluripotent, able to form almost all of the types of cells in the body, stem cells (Evans et al., 1981; 
Thomson et al., 1998; Martin G.R. et al., 1981). Adult stem cells are divided into hematopoietic 
stem cells (HSC) and mesenchymal stem cells (MSC). HSCs, derived from mesoderm and located in 
the red bone marrow, are the stem cells that give rise to all blood cells through the process of 
haematopoiesis (Birbair et al., 2016). MSCs are a population of spindle-shaped clonogenic 
fibroblast precursor cells that proliferate to form colonies, which are able to differentiate into 
multiple specialized cell types, including osteoblast, adipocytes and chondrocytes (Fredenstein et 
al., 1970; Chamberlain et l., 2007; Schipani et al., 2009). 
2.4.1 Mesenchymal stem cells: definition and characterization 
MSCs have been isolated from various tissues and organs, including adipose tissue, bone marrow, 
placental tissue, umbilical cord blood, amniotic fluid, menstrual blood and dental pulp (Pittenger 
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MF et al., 1999; Wagner W et al., 2005; Raynaud CM et al., 2012; Orbay et al., 2012; Allickson JG., 
2011; Huang G.T. et al., 2009; Seifrtova M et al., 2012; Bieback K et al., 2007). These cells were 
immunophenotypically characterized by the expression of multiple surface antigens, such as CD73, 
CD90 and CD105, and the lack of hematopoietic and endothelial markers such as CD11, CD14, 
CD31, CD34 and CD45 (Haynesworth et al., 1992, Lodie et al., 2002 and Suva et al., 2004). As 
reported above, they are characterized by a spindle shaped morphology and the potential to 
differentiate into several mesoderm-derived cell lines, including myogenic, adipogenic, osteogenic, 
neurogenic and chondrogenic lineages (Fig 6). 
 
Fig 6: Multilineage differentiation potential of multipotent MSCS. Under appropriate conditions, MSCs are 
able to differentiate into cell types of different lineages, including bone, cartilage, adipose, muscle, and 
nervous cells. 
 
During the differentiation of MSCs toward a specific cell type, the initial commitment and later 
stages of differentiation are regulated by the interplay among different positive and negative 
stimuli (cytokines, growth factors, extracellular matrix molecules and transcription factors). The 
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commitment and differentiation of MSCs towards adipocytes or osteocytes depend on several 
interacting signaling pathways and the experimental evidence suggested the existence of an 
inverse correlation between adipogenic and osteogenic cell fates (J.N. Beresford et al., 1992).  
The development of a mature osteoblast from a precursor cell can be divided into sub-phases: 
commitment into preosteoblast and proliferation, maturation into mature osteoblasts and matrix 
synthesis, extracellular matrix deposition and mineralization (Neve et al. 2011). When MSCs are 
cultured in osteogenic media they express markers known to be expressed by bone forming 
osteoblasts.  
The osteogenic differentiation of MSCs in vitro has been divided into three main stages (Huang et 
al., 2007). In the first days after the induction it was reported a commitment and cell growth 
phase, followed by early cell differentiation phase (from days 4 to 14) characterized by the 
expression early markers such as the alkaline phosphatase (ALP) and RUNX2 (Aubin, 2001; Quarles 
et al ., 1992). From days 14 to 28 was reported a high expression of late phase markers, including 
osteocalcin and osteopontin, followed by calcium and phosphate deposition (Hoemann et al., 
2009; Huang et al., 2007). 
Adipogenesis is characterized by two main phases: the commitment phase, in which committed 
pre-adipocyte are not distinguishable from their MSC precursors because they show a fibroblastic 
shape but they lost the potential to differentiate into other cell types, and the terminal 
differentiation phase, in which pre-adipocytes become mature adipocytes, changing the 
morphology and acquiring specialized functions, including lipid synthesis and storage (Rosen et al., 
2006; Jumabay et al., 2012). In particular, 1 day after induction, pre-adipocytes re-enter the cell 
cycle and undergo several rounds of mitosis, referred to as mitotic clonal expansion (Davis LA et 
al., 2008; Student AK. et al., 1980). Then cells lose their fibroblastic morphology, accumulate 
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cytoplasmic triglycerides, thanks to the expression of enzymes of involved in fatty acid and 
triacylglycerol biosynthesis, and acquire the appearance and metabolic features of adipocytes 
(Green H. et al., 1974; Student AK. et al., 1980; MacDougald OA et al., 1995; Coleman RA et al., 
1978). 
 
2.4.2 Signaling pathways involved in commitment and differentiation 
Signaling cascades that regulate commitment and differentiation of MSCs depend on the two key 
transcription factors, runt-related transcription factor 2 (RUNX2) and adipogenic-specific 
peroxisome proliferation-activated receptor γ (PPARγ), that mediate the effect of various 
cytokines and are considered the master regulators of osteogenesis and adipogenesis (Zhang X. et 
al., 2006; Zhang L. et al., 2010; Valenti MT et al., 2011).  
RUNX2, member of the Runt transcription factor family, activates and regulates the osteoblast 
differentiation, as it is the target of many pathways such as Wingless type (Wnt), bone 
morphogenetic proteins (BMPs), Hedgehog (HH) and (Nel)-like protein type 1 (NELL-1) (Lee KS et 
al., 2000; Komori et al. 2010; Otto et al. 1997; Pratap et al., 2008).  
Adipogenesis is a multi-step process involving a cascade of transcription factors and cell-cycle 
proteins regulating gene expression and leading to adipocyte development. PPARγ has a central 
role in adipogenesis and its expression is necessary for both commitment and differentiation 
phases (Lehmann et al., 1997; Tzameli et al., 2004; Schopfer et al., 2005). Besides PPAR-γ, there 
are several other transcription factors that regulate adipogenic differentiation, such as C/EBP-α 
and C/EBP-β. Also, during the adipogenic process, Wnt signalling, presumably through Wnt-10b 
expression by pre-adipocytes, is known to decrease adipogenesis in vitro and to play a role in the 
cell fate determination of mesenchymal stem cells (Ross SE et al., 2000). It is believed that 
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endogenous, canonical Wnt signalling maintains preadipocytes in an undifferentiated state by 
inhibiting C/EBP-α and PPAR-γ. When Wnt signalling is suppressed in pre-adipocytes and 
myoblasts, they proceed down the adipogenic lineage (Ross SE et al., 2000). 
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3.AIMS 
Most GNAS-based disorders have the common feature of episodic de novo formation of 
heterotopic ossifications in subcutaneous tissues. The mosaic tissue distribution of HO suggested 
that HO pathogenesis involved an abnormal differentiation of precursor cells, and that GNAS 
defects provided a sensitized background, but the molecular mechanism is still under 
investigation. 
To date, investigations were mainly conducted in mouse models, thus we developed an in vitro 
human model to investigate the differentiation of mesenchymal stem towards adipose or 
osteocyte cell lines, and, in particular, to determine the impact of altered GNAS transcripts 
expression on precursor cells differentiation towards the osteoblast lineage by inducing Gsα 
haploinsufficiency. 
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4. MATERIALS AND METHODS 
4.1 Adipose derived mesenchymal stem cells isolation and characterization 
 4.1.1 ADMSCs isolation and culture 
We isolated adipose derived mesenchymal stem cells (ADMSCs) from abdomen lipoaspirates of 
healthy donors that underwent plastic surgery procedures, after the informed consent signature. 
The ADMSCs isolation protocol consisted of 5 main steps, graphically resumed in figure 7. As a first 
step, the lipoaspirate was washed with sterile phosphate-buffered saline solution (PBS) (Gibco, 
Thermo Fisher Scientific, Waltham, USA) to remove contaminating debris and red blood cells, then 
was subject to enzymatic digestion with 0.075% collagenase (Roche, Mannheim, Germany) for 30 
min at 37°C and centrifugated at 1400 rpm for 10 min to collect dispersed cells. The cell pellet was 
resuspended to count cells with a Hematology analyzer (ABX, Micro60, Horiba ABX) and cells were 
seeded at a density of 6000 cells/cm2 in standard medium, consisting of alpha-Modified Eagle 
Medium-GlutaMax (aMEM-GlutaMax™; Invitrogen, Carlsbad, CA, USA) supplemented with 10% 
fetal bovine serum (FBS; Gibco, Carlsbad, CA, USA) at 37°C in humidified atmosphere containing 
5% CO2. 
 
 Fig 7: Shematic representation of the isolation method used to obtain ADMSCs. 1) Lipoaspirate collection; 
2) cleaning of recovered biological material; 3) enzymatic digestion; 4) cells isolation and count; 5) cells 
plating.  
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 After 48h, fresh medium was added to primary cultures, then cells were passaged every 3 days in 
order to select only adherent cells. In particular, cells were collected using 25% Trypsin 
(EuroCloneS.p.A) and subcultured at a density of 4x103 cells/cm2.  
Mesenchymal stem cells (MSCs) are morphologically characterized by a spindle shape and a small 
cell body with few long and thin cell protrusions. The cell body contains a large round nucleus with 
a prominent nucleolus (Fig. 8). 
 
Fig 8: ADMSCs morphology at passage 3 cultured in alphaMEM with 10%FBS 
Generally, MSCs are defined on the basis of their self-renewal capacity and phenotype, and the 
International Society for Cellular Therapy (ISCT) proposed the following minimum criteria for their 
definition: ability to adhere to plastic surfaces under standard culture conditions and capability to 
differentiate into different mesenchymal lineages.  
We tested our cells for the presence of the above mentioned properties as follow. To assess the 
differentiation potential, we cultured p3 cells in the presence of specific stimuli able to induce 
commitment and differentiation towards the osteocyte or the adipocyte lineages. We selected p3 
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cells because at this passage ADMSCs resulted enough pure, which means that most additional cell 
lines present in lipoaspirates had been lost during the isolation process, young and strong to resist 
in vitro treatments. 
4.1.2 ADMSCs adipocyte differentiation  
ADMSCs were plated at a density of 2 × 103 cells/cm2 and cultured in the alternate presence, 3 
cycles of 7 days, of human MSC adipogenic induction and maintenance medias (Lonza, 
Walkersville, MD USA). As shown in figure 9, the induction of the adipogenic differentiation 
triggered deep phenotypical changes in our cells, that became more spherical and filled with 
intracellular droplets of triglycerides. 
 
Fig 9: ADMSCs morphological changes during the adipogenic induction. 
 
Quantitative measurement of intracellular lipids was performed by lipid staining with Oil Red O 
(hydrophobic) or Nile Red (hydrophilic) stains. The Oil Red O staining protocol required cells 
fixation with 4% formaldehyde for 1h, followed by 3 washes with PBS and 1h staining with fresh 
Oil-Red O solution (Sigma-Aldrich inc, St Louis, MO, USA). The Oil-Red O solution was prepared 
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immediately before the use as follow: 3 parts of a 0,5% stock solution in isopropanol and 2 parts of 
distilled water. The dye was then extracted with 1 ml of isopropyl alcohol and absorbance 
spectrophotometrically determined at a wavelength between 490 nm and 520 nm in a microplate 
reader (Perkin Elmer Wallac 1420 Victor2 Microplate Reader). To determine the intracellular 
triglyceride content was used AdipoRed, commercial kit containing a solution of the hydrophilic 
stain Nile Red, that becomes fluorescent when partitioned in a hydrophobic environment. After 
culture supernatant removal, cells were carefully rinsed with PBS and filled with AdipoRed 
Reagent diluted into PBS at room temperature (RT): for 24-wells plates, 30 µL of reagent were 
added per well, to obtain a final concentrations of 30 µL/mL. After gentle shaking and 10 minutes 
incubation at RT, the fluorescence was read at 572 nm.  
4.1.3 ADMSCs osteoblast differentiation  
For the osteogenic differentiation, 3 × 103 cells/cm2 were grown in the presence of human MSC 
osteogenic medium (Lonza, Walkersville, MD USA) containing α-MEM, 10% FBS and osteogenic 
supplements (1 mM sodium glycerophosphate, 50 μG/mM l-ascorbate, and 10 M dexamethasone) 
(Lonza), and the medium was replaced every 4 days. 
 During commitment and differentiation, cells underwent several morphological and functional 
modifications, including shape changes, from spindled to cuboidal, and the accumulation of 
calcium-rich deposits in the extracellular matrix, that is also the most evident and specific 
observed change (Fig. 10). 
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Fig 10: Calcium-rich deposits accumulation in the extracellular matrix during the ADMSCs osteogenic 
induction. 
 
A commonly tested marker of the osteoblast metabolism is the alkaline phosphatase (ALP), a 
membrane-bound glycoprotein essential for mineral deposition. The TRACP&ALP Assay Kit is a 
biochemical approach to measure ALP activity, based on the conversion of paranitrofenol 
phosphate to p-nitrophenol. After the cell lysis, the substrate of the reaction was added to lysates 
and the absorbance was measured at 405 nm. The activity of the ALP in our ADMSCs was 
measured at different time point (after 2/4/7/14/21 days of osteogenic induction), both in 
differentiated and control cells. 
Since not all induced MSCs underwent differentiation with the same timing, we used an additional 
method based on the ALP staining, the TRACP&ALP double stain Kit, to appreciate the ALP activity 
in single cells directly in culture wells. Components of the substrate solution trigger a chemical 
reaction that generates the Formazan dye, bluish-purple color at pH 9.5, in the presence of 
alkaline phosphatase. Cells were fixed in 24-wells plates with 250 μl of fixation solution (5 minutes 
at RT) and 2 mL of sterile water were added to diluite the fixation solution before its removal. 
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After that the substrate solution was added, the plate was incubated at 37°C for 15-45 minutes. 
Finally, the plate was washed with sterile distilled water and cells were examined in bright field 
(ZEISS Axio Vert.A1) (Fig.11). 
 
Fig 11: Representative image of ALP staining of ADMSCs after 14 days of osteogenic differentiation 
induction. 
Alizarin Red S (ARS) (Sigma Aldrich) staining was used to evaluate calcium-rich deposits released 
from cells into the extracellular matrix. Cells were fixed in ice-cold 70% ethanol, stained with 
Alizarin Red solution (2g/100mL in distillated water) for 30 min, and calcium-rich deposits were 
observed at the microscopy (Fig.12). To quantify the amount of these deposits, cells were 
incubated with 10% acetic acid for 30 minutes and the obtained solution was neutralized with 
NaOH (90 uL for 1mL of Acetic acid), than the absorbance was measured at 405 nm. 
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Fig.12: Representative image of ARS performed in ADMSCs after 14 days of osteogenic differentiation 
induction. 
 
4.2 Confirmation of the in vitro stability of GNAS imprinting by quantification of 
the DNA methylation at the GNAS locus by MS-MLPA 
We evaluated that culture conditions did not interfere with the maintenance of GNAS methylation 
and the differential expression of its transcript, because DNA methylation alteration might lead to 
altered expression data. We performed the semi-quantitative method Methylation-Specific 
Multiplex Ligand-dependent Probe Amplification (MS-MLPA) to determine the DNA methylation 
status at the GNAS locus. The MS-MLPA procedure consists of 5 steps (Figure 13): 1) DNA 
denaturation and hybridization with probes containing the HhaI restriction site; 2) probes ligation 
and digestion with the HhaI methylation sensitive restriction enzyme, whose activity is sterically 
prevented in the presence of DNA methylation; 3) PCR of ligated probes; 4) separation of 
amplification products by capillary electrophoresis; 5) data analysis using the Coffalyser software. 
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Fig.13:Outline of the MS-MLPA procedure 
4.3 GNAS silencing by siRNA transfection 
To in vitro simulate GNAS haploinsufficiency we used specifically designed siRNA targeting 
different GNAS transcripts: one against GNAS exon 6, able to silence both Gsα and XL, and two 
siRNAs complementary to the Gsα-specific exon 1, able to silence specifically the Gsα transcript. 
siRNAs were delivered into cells using the Lipofectamine 2000 (Life Technologies), a cationic 
liposome formulation that can incorporate negatively charged molecules of siRNA allowing them 
to cross the membrane lipid bilayer.  
Briefly, cells were plated at 50% confluence in a 96 wells-plate the day before the transfection. For 
each well, siRNA-Lipofectamine 2000 complexes were prepared as follows: 20 pmol siRNA in 10uL 
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Opti-MEM I Reduced Serum Medium and 0,75 µL of Lipofectamine 2000 in 10uL OptiMEM I 
Reduced Serum Medium, that are then mixed and incubated for 5 minutes at RT before adding to 
each well. The efficiency of gene silencing was evaluated at RNA level by semi quantitative PCR 
and at protein level by western blot. 
4.4 Lineage-specific gene expression analysis 
GNAS-silenced and control cells were seeded at a starting concentration of 4000 cells/cm2 in 6 
wells plates, in the absence or presence of osteogenic-inducing stimuli. Cells were harvested at 
specific time points (2-4-7-14-21 days) and RNA extracted using the TRIzol Reagent (Ambion, 
Thermo fisher scientific, Massachusetts, USA). Briefly, after the removal of the culture medium, 
cells were collected with 1 mL of TRIzol Reagent and, after 10 minutes at RT, 200 μL of chloroform 
were added, tubes were vigorously shacked for 1 minute and centrifuged at 11000 rpm at 4°C for 
15 minutes. The aqueous phases were carefully transferred into new vials containing 500 μL of 
isopropanol and 1 μL of Glycogen, then stored over night (ON) at -20°C. The following day samples 
were centrifuged at 11000 rpm at 4°C for 10 minutes to collect pellets containing nucleic acids 
and, after isopropanol removal, were washed with 150 μL of 70% EtOH, air-dried and RNAs 
suspended in DEPC treated pure water.  
To convert RNA in cDNA we assessed a retrotranscription reactions (RT) as follow: 1000 ng of RNA 
and 4 μL of 5X PrimeScript RT Master Mix (PrimeScript RTase, RNase Inhibitor, Oligo dT Primer, 
Random examers, dNTP Mixture and Mg2+ containing reaction buffer) up to a final volume of 20 
µL. The thermal protocol was: 37°C for 15min (reverse transcription), followed by 85 °C for 5 sec 
(inactivation of enzymes).  
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After RT, a semi-quantitative PCR (semiqPCR) was performed. During the progression of PCR 
cycles, the number of molecules increases exponentially, but it is possible to identify 2 distinct 
phases during the PCR reaction: an exponential phase (linear) and a plateau phase (End-Point) 
(Fig.14). During the linear phase, the initial cDNA amount and the PCR products amount remain 
proportional, thus we can extrapolate the initial amount of amplified nucleic acid comparing the 
expression of a housekeeping gene, a constitutively expressed gene whose expression level is not 
affected by experimental conditions.  
 
Fig.14: PCR phases 
 
SemiqPCRs for each investigated target gene were set up one by one, as we had to determine 
experimentally the number of cycles in the exponential growth phase needed to obtain a signal 
quantifiable by densitometric analysis (Fig.15).  
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Fig.15: Representative image of semiqPCR set up showing that increasing the number of cycles corresponds 
to an increase of signal.  
 
PCR products were separated by agarose gel electrophoresis and the gel image was captured 
digitally with the Visidoc Imaging System (UVP, Cambridge UK) in order to performed a 
densitometry analysis with the ImageJ software.  
We analyzed the expression level of GNAS transcripts and representative genes of the 
differentiation osteogenic pathway. Runt-related transcription factor 2 (RUNX2) is one of the early 
markers of the osteogenic differentiation, followed by Osteopontin (OPN) and alkaline 
phosphatase (ALP). The expression of Dickkopf-related protein 1 (DKK1), Phosphate regulating 
endopeptidase homolog, X-linked (PHEX) and Podoplanin (PDPN) represent late differentiation 
markers.  
Primers sequences are summarized in table 2. 
 FW Primer sequence RW Primer sequence Ta N° cycles 
B-Actin F: CCCAGGACCAGGGCGTGAT R: CAAACATGATCTGGGTCAT 54.4°C 28 cycles 
Gsα F:CCATGGGCTCCCTGGGGAACA R:CCTTGGCATGCTCATAGAATTC 58°C 23 cycles 
RUNX2 F: GTGCGGTGCAAACTTTCTCC R: ACTGACTCTGTTGGTCTCGG 56°C 28 cycles 
20X 22X 24X 40X 
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OPN F: AGAAGCAGAACTCCTAGCC R: AGAGTCGTTCGAGTCAATGG 53°C 30 cycles 
PHEX F: CCTCTTTCTAGTGAGTCAAGG R: GTTCCTTCAACTTGAGGTC 55°C 30 cycles 
PDPN F: CACTGAGACTACAGGTTTGG R: GTTGCCACCAGACTTATAGC 50°C 25 cycles 
Table 2: Primers sequences used in semiqPCR assays. B-Actin, G-protein α subunit (Gsα), Runt-related 
transcription factor 2 (RUNX2), Osteopontin (OPN), alkaline phosphatase (ALP), Phosphate regulating 
endopeptidase homolog, X-linked (PHEX) and Podoplanin (PDPN) 
4.5. Immunofluorescence 
Immunofluorescence (IF) is an imaging technique based on the use of antibodies conjugated to 
fluorescent dyes. In particular, indirect IF requires two antibodies: the unlabeled primary antibody, 
that specifically binds the target antigen, and the fluorophore-labelled secondary antibody, that 
binds the primary antibody and allow the detection of the target molecule. 
To confirm the effect of GNAS silencing on the osteogenic commitment, we investigated the 
expression of Gsα and OPN in GNAS-silenced and control cells, cultured with or without 
osteogenic-inducing stimuli. 
The IF set up was performed in a positive control cell line, the MCF7 breast cancer cell line. The 
following primary antibodies were used: anti-Gsα (sc-135914, Santa Cruz Biotechnologies) and 
anti-OPN (Ab 63856,Abcam) at 1:200 concentration. Primary antibodies were recognized by Alexa 
Fluor 488 goat anti-mouse (Invitrogen, Carlsbad USA) and Alexa Fluor 647 goat anti-rabbit 
(Invitrogen, Carlsbad USA) secondary antibodies, respectively, at 1:1000 concentration. 
To improve signal detection we applied several protocol modifications, the more relevant affecting 
permeabilization and blocking phases. Cells were plated at a cell density of 3 × 103 cells/cm2 in 24-
wells plates on glass coverslips. After 24h, cells were fixed using 4% paraformaldehyde (PFA) in  
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PBS pH 7.4 for 10 min at RT. To block unspecific binding of primary antibodies we used a solution 
containing 1% BSA in 22.52 mg/mL glycine in PBST (PBS+ 0.1% Tween 20) for 30 min, then cells 
were incubated ON with the primary antibody in 1% BSA in PBST in a humidified chamber at 4°C. 
Incubation with the secondary antibody in 1% BSA was performed for 1 h at RT in the dark and, 
finally, coverslips were mounted with a drop of ProLong® Gold Antifade Mountant with DAPI 
(Thermo fisher).  
Subsequently, we also tried to set up the double IF to examine simultaneously the co-distribution 
of Gsα and OPN. We tested both simultaneous and sequential immunofluorescence protocols. 
Briefly, the simultaneous procedure is based on the simultaneous incubation with Gsα and OPN 
primary antibodies, followed by simultaneous addition of their secondary antibodies. With the 
sequential method the first primary antibody is incubated 1 h at RT and then the second one is 
incubated ON at 4°C. The following day, the secondary antibodies are incubated sequentially 1h at 
RT each. The above mentioned procedures did not give substantial differences, so we decided to 
adopt the simultaneous protocol.  
In ADMSCs we were not able to visualize the co-expression of the two investigated antigens, thus 
we introduced additional changes to the protocol. Instead of 4% PFA we used cold acetone to fix 
cells, and triton 0,03% was added to the permeabilization solution. Moreover, we adjusted 
primary antibody concentrations, Gsα at 1:100 and OPN at 1:50, whereas the anti-mouse 488 and 
the 647 anti-rabbit secondary antibody were used at 1:500 and at 1:100 concentration, 
respectively. 
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5. RESULTS 
According to the current knowledge, the ectopic bone formation observed in patients affected 
with GNAS-related disorders likely resulted from an abnormal differentiation of MSCs and/or more 
committed precursor cells located within soft connective tissues. 
To date, investigations were mainly conducted in the murine model because of the difficulty to 
obtain tissue samples of ectopic bone from AHO/PHP patients, thus the knowledge of molecular 
mechanisms underlying HO development in humans is still incomplete.  
To this purpose, we set up an in vitro model of human ADMSCs isolated from surgically removed 
samples of subcutaneous fat of healthy donors.  
In the first phase of the project, in order to set up the in vitro model, we isolated and 
characterized ADMSCs, confirming their ability to differentiate into osteoblasts and adipocytes, 
but also their epi/genetic and transcriptional stability. 
In the second phase of the project, in order to investigate the mechanisms underlying HO 
formation in GNAS-related disorders, we evaluated effect of Gsα haploinsufficiency in our ADMSCs 
by silencing GNAS in the presence/absence of differentiation stimuli. 
5.1 Differential methylation stability at GNAS DMRs and Gsα biallelic expression 
We evaluated the methylation state at GNAS DMRs in genomic DNA extracted from cells cultured 
in presence/absence of differentiation stimuli and harvested at different time points (t2-t4-t7-t14 
e t21). Table 3 shows the results of GNAS MS-MLPA data analysis obtained by Coffalyser software 
analysis, in which methylation ratios between 0,7 and 0,3 are considered representative on an 
hemimethylated wild type status, while upper and lowers values represent an alteration of GNAS 
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DMRs methylation. In particular, methylation ratio values close to 0 highlight the presence of a 
loss of methylation (LoM), while values greater than 0.7 represent a gain of methylation (GoM). 
At all investigated time points, we obtained values confirming the preservation of GNAS 
imprinting, or rather an hemimethylated state of GNAS DMRs. In particular, mean measured 
methylation ratios in all tested samples were comprised into the mean range values determined in 
the control population of not induced cells at t0, 0,54±0,08. For example, at t21, we measured the 
following methylation ratios: 55±0,6 and 0,54±0,08 in the presence/absence of differentiation 
stimuli, respectively (Tab.3 ).  
These data confirmed that different tested culture conditions did not interfere with the 
maintenance of GNAS DMRs methylation. Any difference in GNAS transcripts expression observed 
during the following phases of the present study were consequence of the in vitro cell 
manipulation. 
 
 
Tab.3: Representative table showing methylation ratios of GNAS DMRs obtained by MS-MLPA analysis. The 
first column shows STX16 and GNAS probes, according to their order on chromosome 20. In the second 
column, results obtained on ADMSC at day 0 are reported, while in the last columns are reported 
methylation ratios determined in ADMSCs after 21 days of culture with or without the osteogenic 
differentiation medium. 
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Several studies demonstrated that Gsα may be subject to monoallelic or biallelic expression 
according to the specific tissue (Mantovani G et al., 2002). In particular, it was demonstrated a 
biallelic expression of Gsα in the adipose tissue (Mantovani et al., 2004), but, actually, no data 
about the expression in mesenchymal stem cells isolated from adipose tissue were available, thus 
we evaluated Gsα expression in our cell lines. Briefly, we screened our ADMSCs at genomic level to 
find informative cell lines, which means heterozygous at the rs7121T/C polymorphism in exon 5. 
Then, testing their mRNAs, we confirmed the biallelic expression of Gsα, because, in informative 
samples, both alleles were present after the digestion with the restriction enzyme (Figure 16). 
 
Fig:16 Figure showing the gel electrophoresis separation of Gsα cDNA samples after the digestion at the 
polymorphic site in exon 5 by FOKI endonuclease, confirming the presence of transcripts deriving from both 
parental alleles.  
5.2 OB induction increases ALP activity 
The alkaline phosphatase (ALP) is an early marker of osteogenesis, whose function is essential for 
the mineral deposition. The induction of the osteoblast differentiation stimulated the ALP activity 
in our ADMSCs, with statistically significant differences in the measured ALP activity starting from 
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day 4 of in vitro osteoblast induction (Day 4 NI=0,10±0,01, I=0,238±0,02). The ALP activity 
increased exponentially with the days of treatment, reaching the maximum at day 21, I=1,45±0,08 
vs NI=0,1±0,01, that represented an increase of 14.5±2 fold respect with non induced control cells 
(Fig. 17). 
 
Fig.17: Graph showing the Alp Activity measurement in ADMSCs. The ALP activity (mean±SEM) showed an 
exponential increase in induced cells (dot blots, black) since day 4 (*p < 0.05), compared to non induced 
cells (squares, grey)  
 
To evaluate the contribute of single cells to the measured increase of ALP activity, we also 
performed the direct staining (Figure 18).  
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Fig.18: Represenative figure showing the increase of the ALP activity after the osteoblast induction of 
ADMSCs by direct staining. The activation of the ALP is appreciable starting from day 2 of induction by the 
production of a localized blue colour, which become more intense in the following days. (optical 
microscope with 4X magnification) 
 
5.3 Mineralization process is induced during OB differentiation 
To evaluate cells ability to deposit calcium into the extracellular matrix, thus their differentiation 
into functional osteoblasts, we used the Alizarin Red S staining. 
At day 0, no mineral deposits were detectable. After the osteoblast induction, small, sparsely and 
densely stained nodules started to appear since day 7 of treatment. After 28 days, the monolayer 
was densely stained and calcium-rich extracellular deposits visible even without the microscope 
(Figure 19).  
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Fig.19: Representative figures of ADMSCs cultured to stimulate the osteogenic differentiation up to 28 days 
and stained with the Alizarin Red S. Mineralization in induced cells appeared progressive and extensive 
compared to control cells (NI). (optical microscope, 4X and 10X magnification) 
 
We also quantified the amount of stained deposits by measuring the absorbance at 405 nm after 
dissolution with acetic acid. Results showed in Figure 20 demonstrated that the accumulation of 
calcium deposits during OB induction (dot blots, black) increased day by day with respect to non 
induced control cells (squares, grey). In particular, at days 7, 14, 21 and 28 mean absorbance 
values in induced cells were 0,172±0,01, 0,236±0,06, 0,377±0,02 and 0,743±0,07, respectively. 
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Fig.20: Graph showing the quantification of calcium-deposits in the extracellular matrix after the osteogenic 
differentiation of ADMSCs. Dot blots (black) represent while squares (grey) non-induced control cells. Data 
expressed as mean of three replicates ± SEM. 
 
5.4 Osteogenic lineage-specific markers are upregulated by OB induction 
We measured the expression of the osteogenic markers RUNX2 and his responsive gene OPN. As 
expected, their expression was found up-regulated in induced samples since the day 7, further 
demonstrating the ability of our ADMSC cell lines to differentiate toward the osteoblast lineage. 
Data obtained by semiq-PCR analysis of transcripts expression showed no significant differences in 
control non induced cells at all tested time points, and an increase of RUNX2 osteogenic marker 
expression in induced cells since day 2 (RUNX2 I=1,33±0,8 RUNX2 NI=1±0,6 ), with statistically 
significant differences at both days 7 (OPN I=1,604±0,63; RUNX2 I=2,83±0,7) and 14 (OPN 
I=2,153±0,84; RUNX2=4,8±2,5) (Figure 21). 
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Fig.21: Graphs showing the expression analysis of RUNX2 (upper panel) and OPN (lower panel) in ADMSCs. 
Transcript levels were normalized to the expression level of the housekeeping gene β-actin and to markers 
expression at day 0 Data expressed as mean of three replicates ±SEM(*p < 0.05). 
 
5.5 GNAS transcripts expression is not affected by OB induction  
To evaluate the effect of the osteoblast induction on the expression of GNAS transcripts, we 
performed semiq-PCR, showing that Gsα and XLαs expression had no significant differences 
between induced and control ADMSCs during the 21 days of treatment (Figure 22). 
* 
* 
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Fig.22: Graphs showing the expression of GNAS transcripts Gs alpha and XLas in ADMSCs. Gsα and XLαs 
were quantified by semiq-PCR at several time points (t2, t4, t7, t14 and t21). Relative expression was 
normalized to day 0. Data expressed as mean of duplicates ± SEM 
 
 
5.6 GNAS siRNAs induces an efficient and specific silencing of GNAS transcripts and 
simulates haploinsufficiency 
In order to validate the hypothesis that GNAS transcriptional alterations caused an accelerated 
osteoblast differentiation of precursor cells and an enhanced expression of osteogenic markers, 
we silenced GNAS using different specific siRNAs. In particular, we used one siRNA targeting GNAS 
exon 6 (si5890), thus able to silence both Gsα and XLαs, and we designed two custom siRNAs 
complementary to the Gsα-specific exon 1 (s455731 and s455692), able to specifically silence the 
Gsα transcript. The efficiency and the specificity of siRNAs were tested by semiq-PCR. 
As reported in the Graph 24, the analysis confirmed a significant decrease of Gsα expression in 
silenced samples: at day 2 control cells NI=0,81±0,05, SINI5890=0,141±0,03, SINI731=0,171±0,06, 
SINI692=0,159±0,04; at day 4 NI=1,08±0,18, SINI5890=0,099±0,04; SINI731=0,163±0,03; 
SINI692=0,209±0,02; at day 7 NI =0,75±0,23, SINI5890=0,03±0,2; SINI 731=0,39±0,03; SINI 692= 
0,309±0,04 at day 14 control cells NI=1,1±0,2 and silenced cells SINI5890=0,713±0,02, 
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SINI731=0,438±0,01, SINI692=0,577±0,04. The expression of Gsα was downregulated up to 14 
days after the transfection, then it gradually reactivated, reaching values similar to those detected 
in control cells at day 21 control cells NI=1,06±0,1 and silenced cells SINI5890=1,12±0,05, 
SINI731=1,02±0,22, SINI692=1,00±0,16 (Figure 23).  
 
Fig.23: Graph resuming the Gsα mRNA expression analysis quantified by semiq-PCR to test the effect of 
GNAS silencing. Relative expression of Gsα was normalized to day 0. Data expressed as mean of triplicates 
±SEM. 
 
To assess the specificity of our GNAS siRNAs, we evaluated the XLαs expression and, as shown in 
Figure 24, only the siRNA si5890 targeting GNAS exon 6 was able to silence XLαs, while siRNAs 
towards Gsα-specific exon 1 had no effect on XLαs expression (at day 2 NI=14,21±0,01 
SINI5890=0,08±0,001, SINI731=11,9±0,015, SINI692=11,1±0,02; at day 4 NI=4,9±0,9, 
SINI5890=0,07±0,002, SINI731=3,8±0,01, SINI692=3,82±0,015) 
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Fig 24: Graph showing the XLαs mRNA expression analysis. Data reported as mean ±SEM (*p<0.05) 
 
5.7 The effect of GNAS silencing on extracellular matrix mineralization and ALP 
activity  
To evaluate the effects of GNAS silencing on ADMSC differentiation, we used the ALP assay and 
the Alizarin Red staining. 
The ALP staining revealed that not all cells underwent differentiation, as highlighted by the 
presence of two subpopulations of cells with different morphological and biochemical 
characteristics: the first one with a high ALP activity and an osteoblast-like phenotype, and the 
other one with undetectable ALP activity, which probably corresponded to undifferentiated 
ADMSCs (Figure 25). 
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Fig 25: Representative figures showing the ALP staining of ADMSCS cultured in presence and in absence of 
osteogenic differentiation medium (A and B) and GNAS-silenced ADMSCs cultured without differentiation 
stimuli (C and D) (optical microscope, 4X and 10X magnification). 
The quantification of the ALP activity (Fig.26) showed an increase starting from day 7 in all silenced 
samples, which displayed an intermediate phenotype between cells grown in control and inducing 
medium. Statistically significant differences (*p<0.05) were observed at days 7-14-21 with respect 
to non induced-cells (Abs 405nm at day 7 SINI5890=1,67±0,12; SINI731=0,34±0,13; 
SINI692=0,38±0,04; at day 14 SINI5890=0,48±0,15; SINI731=0,46±0,21; SINI692=0,62±0,26; at day 
21 SINI5890=0,78±0,2; SINI 731=0,85±0,03; SINI 692= 0,82±0,1) 
A B 
C D 
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Fig.26: Graph showing the Alp activity in GNAS-silenced and control cells. Data expressed as mean 
(4replicates/well) ± SEM. All data were normalized respect to non induced cells.  
Alizarin red staining pointed out that the osteoblast phenotype acquired by silenced cells seemed 
to be functionally incomplete, as silenced cells were not able to mineralize the extracellular matrix 
as control induced cells did, forming only few, rare and little calcium deposits (Figure 27). 
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Fig.27: Figures showing ARS-stained ADMSCs at day 28. 
 
 
5.8 GNAS silencing is associated with an increase of osteoblast-specific markers  
To investigate the effect of GNAS silencing on the expression of osteoblast-specific markers, we 
evaluated RUNX2 and OPN expression in GNAS-silenced and control cells, cultured with or without 
osteogenic-inducing stimuli.  
As shown in figure 28, GNAS haploinsufficiency resulted in a significant upregulation of RUNX2 and 
OPN, with pattern and timing similar to those observed in induced cells.  
RUNX2 expression was significantly increased at all tested time points in GNAS-silenced cells (At 
day 2 SINI589=2,33±0,8; SINI731=1,92±0,4; SINI692=1,66±1; at day 4 SINI589=2,5±1,1; 
SINI731=5,81±1,1; SINI692=4,01±1,02 ; at day 7 SINI589=3,63±1; SINI731=4,31±0,35; 
SINI692=4,18±0,32; at day 14 SINI589=4,33±1,05; SINI731=2,35±1;SINI692=4,25±1,1; at day 21 
SINI589=3,62±0,7; SINI731=3,55±1,03; SINI692=4,02±0,95. 
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OPN expression was enhanced in GNAS-silenced cells with statistically significant differences with 
respect to non induced cells at all time points (at day 4 SINI5890=10,971±3,350; 
SINI731=12,751±1,08; SINI692=37,831±5,35; at day 7 SINI5890=29,166±4,10; SINI731=27,79±3,21; 
SINI692=62,85±9,19) reaching a maximum level of expression at day 14, resembling the pattern of 
osteogenic-induced cells (OPN at day 14 SINI5890=71,021±19,20; SINI731=85,708±22,77; 
SINI692=83,94±18,62; I=91,01±19,82) then the expression decreases at day 21 (at day 21 
SINI5890=18,67±1,47; SINI731=37,55±5,01; SINI692=50,36±9,87).  
 
Fig. 28: Graph showing the expression of osteogenic markers after GNAS silencing. Expression of RUNX2 
and OPN were normalized to β-actin. Relative expression of each transcript was normalized to day 0 and NI 
cells (p < 0.05). Data expressed as mean ±SEM. 
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5.9 Co-localization of GNAS-transcript and osteogenic markers in ADMSCs. 
To visualize at cellular level the expression of specific markers, we set up the immunofluorescence 
assays in MCF7 control cells (Fig.29), using primary antibodies raised against Gsα and OPN 
proteins. In order to be able to examine also the co-distribution of these two antigens, we 
performed a double immunofluorescence procedure. 
 
Fig.29: Representative image showing the co-localization of Gsα (green) and OPN (purple) in MCF7 cells. 
Nuclear DNA was labelled with DAPI ( blue). 
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The analysis performed in ADMSCs after day 14 of osteoblast induction, showed the co-
localization of Gsα and OPN, but the protocol needs further improvement to before testing GNAS-
silenced cells (Fig.30). 
 
 
Fig 30: Representative image showing the co-localization of Gsα (green) and OPN (purple) in ADMSCs. 
Nuclear DNA was labelled with DAPI (blue). 
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5.10 GNAS-silenced cells expressed osteocytes markers. 
Due to the observed lack of a productive deposition of mineralized matrix by our GNAS-silenced 
ADMSCs, we hypothesized an accelerated differentiation towards an osteocyte-like phenotype 
and we evaluated the expression of early markers of osteocyte cells PHEX and PODOPLANIN.  
As it is possible to appreciate in the figure 31, as early as day 7 after transfection, silenced cells 
expressed both PHEX and PODOPLANIN, a feature absent in induced controls cells. This 
observation supported the hypothesis that haploinsufficiency of Gsα caused the commitment of 
ADMSCs towards the osteoblast lineage accompanied by a quick shift to an osteocyte-like 
phenotype, that could explain the observed lack of in vitro extensive ossification. 
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Fig.31: Image of the expression of early osteocyte markers in ADMSCs. PHEX and PDPN expression was 
analyzed after GNAS-silencing at representitative time points (day 7-14-21). 
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6. DISCUSSION 
Despite the growing knowledge on the process of heterotopic ossification in rare genetic disorders 
and, in particular, in AHO/PHP, the pathophysiological mechanisms by which alterations of cAMP 
signaling lead to ectopic bone formation in the context of mesenchymal tissues is not fully 
understood.  
To date, investigations have been mainly conducted in mouse models because of the difficulty to 
obtain HO tissue samples surgically removed from AHO/PHP patients, thus data describing the 
molecular and functional characterization of human HO forming cell lineages are still lacking.  
The present research first aim was the development of an in vitro human model to investigate the 
differentiation of adipose-derived mesenchymal stem cells (ADMSCs), and, in particular, to 
determine the impact of altered GNAS expression on precursor cells differentiation towards the 
osteoblast lineage and to elucidate GNAS role in ectopic bone formation in GNAS-related diseases. 
Firstly, we isolated and characterized ADMSC cell lines from healthy donors, confirming that they 
fulfilled generally accepted standards for mesenchymal stem cells identification, and determined 
that culture conditions did not interfere with GNAS imprinting and the differential expression of its 
transcript (Dominici M., 2006, Weinstein et al., 2001; Plagge A. et al., 2005; Nygren AO et al., 
2005). 
Then, we silenced GNAS in our cell model of ADMSCs with the aim to analyze the effect of GNAS 
haploinsufficiency on the osteogenic differentiation ability of precursor cells. 
In 2011, Pignolo and colleagues demonstrated in a mouse model that the heterozygous 
inactivation of Gnas caused the upregulation of multiple transcripts normally associated with the 
osteoblast differentiation of adipose stromal cells in vitro (Pignolo et al., 2011). Their data 
suggested that, in GNAS-related disorders, HO resulted from decreased GNAS expression, 
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promoting osteogenesis and suppressing adipogenesis in multipotent connective tissue progenitor 
cells. In accordance with their findings, we observed in our GNAS-silenced ADMSCs that Gs alpha 
haploinsufficiency promoted the commitment into the osteoblastic differentiation pathway.  
GNAS silencing was performed using different siRNAs able to silence both Gsα and XLαs or 
exclusively the Gsα transcript, which allowed us to determine the impact of single GNAS 
transcripts on ectopic bone formation. In particular, we observed no significant differences due to 
the use of siRNAs targeting the common GNAS exon 6 or the Gsα-specific exon 1, further 
demonstrating our hypothesis that the formation of ectopic bone is predominantly Gsα-mediated 
rather than XLαs-mediated (Cheeseman et al., 2012).  
During differentiation, GNAS-silenced cells underwent several morphological and functional 
modification including shape changes and up regulation of different osteogenic markers (ALP, 
RUNX2 and OPN) with pattern and timing similar to those observed in induced cells demonstrating 
that Gs alpha haploinsufficiency might to promote and increase the ADMSC commitment to 
osteoblastic differentiation.  
The evaluation of the ability of silenced cells to mineralize the extracellular matrix revealed that 
our ADMSCs were able to form only very small and sparse calcium deposits compared to induced 
control cells, leading to the hypothesis that the observed reduced mineralization was a 
consequence of too fast maturation of pre-osteoblast into mature osteocytes. In order to evaluate 
this hypothesis, we investigated the early osteocyte markers PHEX and PDPN, and expression data 
showed their upregulation since day 7 of treatment. Actually, the best fitting interpretation is that 
Gsα haploinsufficiency promoted ADMSCs differentiation into pre-osteoblasts, expressing well-
known early osteogenic markers such as RUNX2 and OPN, but then they underwent a failure of 
terminal differentiation into mature osteoblasts and quickly differentiated into osteocytes. These 
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findings were in agreement with a recent study performed in mice lacking Gsα in the osteoblast 
lineage (Gsα osxKO), with a markedly reduced number of mature osteoblasts and abundant 
osteocytes, where authors assessed that the absence of Gsα led to a rapid differentiation into 
osteocytes of the osteoblast lineage (Wu J.Y. et al., 2011). 
Moreover, in our study we observed that GNAS-silenced ADMSCs grown in the presence of 
osteogenic differentiation stimuli showed an improved ALP activity and remarkably stronger 
mineralization ability compared with only osteoblast-induced cells, suggesting that Gsα 
haploinsufficiency enhanced their osteogenic commitment. Previous works demonstrated the 
same accelerated ALP expression, as well as an earlier and more extensive extracellular 
mineralization ability than wild type cells, in other in vitro models, including calvarial osteoblast 
cells from Gsα osxKO mice subject to osteogenic differentiation and adipose soft tissue stromal 
cells (STSCs) from Gnas+/- mice (Wu J.Y. et al., 2011, Pignolo et al., 2011).  
In conclusion, this project provides evidence that human adipose-derived mesenchymal stem cells, 
ADMSCs, are a good in vitro model to study the osteoblast differentiation pathway and to improve 
the knowledge about formation of heterotopic ossification in GNAS-related diseases.  
Furthermore, we demonstrated that GNAS silencing promotes ADMSCs commitment towards the 
osteoblast lineage, even in the absence of additional osteogenic-inducing stimuli.  
Finally, the detection of the expression of early osteocyte markers in the early stages of 
differentiation, led to the hypothesis that Gsα haploinsufficiency might be associated with a 
premature shift towards the osteocyte phenotype.  
Moreover, these data further support that the formation of ectopic bone is predominantly Gsα-
mediated as we observed no significant differences due to the use of different siRNAs targeting 
specific GNAS sequences.  
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Ongoing and future studies will confirm data collected up to now, by replicating obtained 
observations in additional ADMSCs lines from healthy donors and PHP patients, and in MSCs from 
tissues different from fat. Additional experiments will be performed to evaluate to effect of GNAS 
haploinsufficiency on the adipogenic differentiation pathway, and, in particular, how it interacts 
with the osteoblast differentiation.  
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